Cargando…

Medication and patient factors associated with adherence to pulmonary hypertension targeted therapies

The aims of this study were to investigate the medication adherence of patients on pulmonary hypertension (PH)-targeted therapies and uncover factors that might influence adherence values. Patients taking at least one specialist medicine (sildenafil, tadalafil, bosentan, ambrisentan, iloprost, epopr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grady, Duncan, Weiss, Marjorie, Hernandez-Sanchez, Jules, Pepke-Zaba, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731720/ https://www.ncbi.nlm.nih.gov/pubmed/29099657 http://dx.doi.org/10.1177/2045893217743616

Ejemplares similares

Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017)

Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment
por: Toshner*, Mark, et al.
Publicado: (2014)

Acute and chronic dissection of pulmonary artery: new challenges in pulmonary arterial hypertension?
por: Florczyk, Michał, et al.
Publicado: (2017)

Quality of life in patients with chronic thromboembolic pulmonary hypertension
por: Mathai, Stephen C., et al.
Publicado: (2016)

COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey
por: Belge, Catharina, et al.
Publicado: (2020)

Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension
por: Toshner, Mark R., et al.
Publicado: (2010)

Maximal Cardiac Output Determines 6 Minutes Walking Distance in Pulmonary Hypertension
por: Deboeck, Gaël, et al.
Publicado: (2014)

The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease
por: Hadinnapola, Charaka, et al.
Publicado: (2015)

The prognostic ability of cardiac output determined by inert gas rebreathing technique in pulmonary hypertension
por: Robertson, Lucy, et al.
Publicado: (2022)

A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension
por: Bunclark, Katherine, et al.
Publicado: (2021)

Author's reply
por: Pepke-Zaba, Joanna
Publicado: (2012)

Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension
por: Swietlik, Emilia M., et al.
Publicado: (2021)

Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience
por: Hoole, Stephen P, et al.
Publicado: (2020)

Pulmonary hypertension in chronic lung disease and hypoxia
por: Nathan, Steven D., et al.
Publicado: (2019)

Endothelin ET(A) receptors predominate in chronic thromboembolic pulmonary hypertension
por: Southwood, Mark, et al.
Publicado: (2016)

Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries
por: Schweikert, Bernd, et al.
Publicado: (2014)

Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension
por: Soon, Elaine, et al.
Publicado: (2011)

Lifting the fog in intermediate-risk (submassive) PE: full dose, low dose, or no thrombolysis?
por: Bhamani, Amyn, et al.
Publicado: (2019)

Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Association Between Copayment and Adherence to Medications for Pulmonary Arterial Hypertension
por: Schikowski, Erin M., et al.
Publicado: (2022)

Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study
por: Karia, Nina, et al.
Publicado: (2023)

(18)FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study
por: Hagan, Guy, et al.
Publicado: (2011)

Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension
por: Howard, Luke S.G.E., et al.
Publicado: (2013)

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
por: Toshner, Mark, et al.
Publicado: (2022)

Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension
por: Condliffe, Robin, et al.
Publicado: (2012)

Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival
por: Schwiening, Max, et al.
Publicado: (2022)

Presentation and management of pulmonary artery sarcoma
por: Wong, Han Hsi, et al.
Publicado: (2015)

Evaluation of medication adherence in hypertensive patients and influential factors
por: Boratas, Selma, et al.
Publicado: (2018)

Patient Adherence With Hypertension Medication
por: Wogen, Jenifer
Publicado: (2004)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension
por: Jose, Arun, et al.
Publicado: (2017)

Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis
por: Owen, Nicola E., et al.
Publicado: (2020)

Idiopathic pulmonary arterial hypertension and co-existing lung disease: is this a new phenotype?
por: Peacock, Andrew J., et al.
Publicado: (2020)

Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
por: Morrell, Nicholas W., et al.
Publicado: (2013)

Isolated large vessel pulmonary vasculitis as a cause of chronic obstruction of the pulmonary arteries
por: Hagan, Guy, et al.
Publicado: (2011)

Knowledge about hypertension and factors associated with the non-adherence to drug therapy
por: Barreto, Mayckel da Silva, et al.
Publicado: (2014)

PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic
por: Godinas, Laurent, et al.
Publicado: (2021)

Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021
por: Simonneau, Gérald, et al.
Publicado: (2023)

Medication Adherence in Korean Hypertensive Patients
por: Cho, Young Gyu
Publicado: (2018)

Current Situation of Medication Adherence in Hypertension
por: Vrijens, Bernard, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qjl709dc0t8upkedprgejrt2j3